Stock FYB FORMYCON AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Formycon AG Börse Stuttgart

Equities

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Real-time Estimate Tradegate
Other stock markets
 10:19:11 03/06/2024 BST 		5-day change 1st Jan Change
45.1 EUR +2.38% Intraday chart for Formycon AG +5.26% -20.77%
04-25 Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-18 Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 319 530 651.7 1,309 904.6 782.3 - -
Enterprise Value (EV) 1 296.6 487.8 626.6 1,648 904.6 767.2 755.1 702.9
P/E ratio -139 x -98.4 x -48.4 x 33.4 x 11.9 x -51.7 x -1,477 x 11.4 x
Yield - - - - - - 0.55% -
Capitalization / Revenue 9.41 x 15.5 x 17.6 x 30.8 x 11.6 x 13.1 x 10.1 x 4.58 x
EV / Revenue 8.75 x 14.3 x 17 x 38.8 x 11.6 x 12.8 x 9.74 x 4.11 x
EV / EBITDA -212 x -101 x -50.6 x -104 x 596 x -41.8 x 70.4 x 7.69 x
EV / FCF -123 x -86.1 x -42.1 x -36.1 x - -9.04 x -31.7 x 17.2 x
FCF Yield -0.81% -1.16% -2.38% -2.77% - -11.1% -3.16% 5.81%
Price to Book 6.62 x 8.57 x 11.6 x 3.67 x - 1.37 x 1.35 x 1.21 x
Nbr of stocks (in thousands) 10,000 10,000 11,047 15,130 16,039 17,660 - -
Reference price 2 31.90 53.00 59.00 86.50 56.40 44.30 44.30 44.30
Announcement Date 18/05/20 17/05/21 18/05/22 27/04/23 25/04/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 33.9 34.23 36.96 42.5 77.7 59.72 77.53 171
EBITDA 1 -1.4 -4.81 -12.39 -15.87 1.518 -18.36 10.72 91.36
EBIT 1 -2.3 -5.725 -13.33 -17.73 -0.369 -23.27 -10.87 76.22
Operating Margin -6.78% -16.73% -36.07% -41.72% -0.47% -38.96% -14.02% 44.58%
Earnings before Tax (EBT) 1 -2.291 -5.923 -13.47 36.6 79.07 -10.38 3.9 85.58
Net income 1 -2.293 -5.926 -13.48 35.99 75.8 -14.6 1.26 67.42
Net margin -6.76% -17.31% -36.46% 84.69% 97.55% -24.45% 1.63% 39.43%
EPS 2 -0.2293 -0.5387 -1.218 2.590 4.720 -0.8575 -0.0300 3.894
Free Cash Flow 1 -2.403 -5.662 -14.88 -45.64 - -84.9 -23.85 40.83
FCF margin -7.09% -16.54% -40.26% -107.39% - -142.17% -30.76% 23.88%
FCF Conversion (EBITDA) - - - - - - - 44.69%
FCF Conversion (Net income) - - - - - - - 60.57%
Dividend per Share 2 - - - - - - 0.2433 -
Announcement Date 18/05/20 17/05/21 18/05/22 27/04/23 25/04/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 S1
Net sales -
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income 1 1.804
Net margin -
EPS 2 0.1130
Dividend per Share -
Announcement Date 30/08/23
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - 339 - - - -
Net Cash position 1 22.4 42.2 25.2 - - 15.2 27.2 79.5
Leverage (Debt/EBITDA) - - - -21.36 x - - - -
Free Cash Flow 1 -2.4 -5.66 -14.9 -45.6 - -84.9 -23.9 40.8
ROE (net income / shareholders' equity) -5.63% -10.2% -21.7% 17.5% - -3.4% -0.05% 9.55%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 4.820 6.190 5.070 23.60 - 32.30 32.90 36.70
Cash Flow per Share 2 - -0.4600 -1.280 -1.380 - -1.690 1.720 3.630
Capex 1 0.92 0.56 0.7 26.8 - 60.1 55 52.4
Capex / Sales 2.72% 1.63% 1.9% 62.97% - 100.68% 70.87% 30.63%
Announcement Date 18/05/20 17/05/21 18/05/22 27/04/23 25/04/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Formycon AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
44.3 EUR
Average target price
86 EUR
Spread / Average Target
+94.13%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. FYB Stock
  4. FYB Stock
  5. Financials Formycon AG
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW